The role of FERMT2 in the tumor microenvironment and immunotherapy in pan-cancer using comprehensive single-cell and

Guang-Hao Wu1, Chao He2, Gang Che2

  • 1School of Clinical Medicine, Hangzhou Normal University Medical College, Hangzhou, China.

Heliyon
|May 10, 2024
PubMed

Insights

FERMT2 influences cancer progression and impacts tumor microenvironment immunity. Elevated FERMT2 expression correlates with poor prognosis and altered immune cell infiltration, highlighting its role in cancer development and potential therapeutic targeting.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • FERMT2 is implicated in integrin-linked kinase signaling and epithelial-mesenchymal transition, processes vital for tumor initiation, progression, and invasion.
  • The precise role of FERMT2 within the tumor microenvironment (TME) and its implications for cancer immunotherapy remain largely undefined.

Purpose of the Study:

  • To comprehensively analyze the prognostic significance of FERMT2 in various cancer types.
  • To investigate the association between FERMT2 expression and immune characteristics within the TME.
  • To explore the molecular mechanisms and cellular interactions involving FERMT2 in cancer.

Main Methods:

  • Kaplan-Meier analysis for prognostic significance.
  • Enrichment analysis for molecular mechanisms.
  • Immunedeconv package for TME immune characteristics.
  • Single-cell sequencing for cell-type specific expression.
  • Multiplex immunofluorescence staining for co-expression analysis.

Main Results:

  • Elevated FERMT2 expression is significantly correlated with unfavorable prognosis in certain cancer types.
  • FERMT2 expression strongly associates with immune checkpoint molecules, immune cell infiltration, microsatellite instability (MSI), and tumor mutational burden (TMB).
  • FERMT2 correlates with fibroblast activation, migration, and growth pathways, and shows co-expression with cancer-associated fibroblasts (CAFs) and alpha-smooth muscle actin (α-SMA).

Conclusions:

  • FERMT2 is a significant prognostic biomarker in specific cancers, linked to unfavorable outcomes.
  • FERMT2 expression modulates the tumor immune microenvironment and fibroblast activity.
  • Targeting FERMT2, particularly its co-expression in CAFs, may offer novel therapeutic strategies in cancer treatment.

Related Concept Videos